Literature DB >> 32553252

Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy.

Raj R Makkar1, Philipp Blanke2, Jonathon Leipsic2, Vinod Thourani3, Tarun Chakravarty4, David Brown5, Alfredo Trento4, Robert Guyton6, Vasilis Babaliaros6, Mathew Williams7, Hasan Jilaihawi7, Susheel Kodali8, Isaac George8, Michael Lu9, James M McCabe10, John Friedman4, Richard Smalling11, Shing Chiu Wong12, Shahram Yazdani13, Deepak L Bhatt14, Jeroen Bax15, Samir Kapadia16, Howard C Herrmann17, Michael Mack5, Martin B Leon8.   

Abstract

BACKGROUND: Subclinical leaflet thrombosis, characterized by hypoattenuated leaflet thickening (HALT) and reduced leaflet motion observed on 4-dimensional computed tomography (CT), may represent a form of bioprosthetic valve dysfunction.
OBJECTIVES: The U.S. Food and Drug Administration mandated CT studies to understand the natural history of this finding, differences between transcatheter and surgical valves, and its association with valve hemodynamics and clinical outcomes.
METHODS: The PARTNER 3 (The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aortic Stenosis) CT substudy randomized 435 patients with low-surgical-risk aortic stenosis to undergo transcatheter aortic valve replacement (n = 221) or surgery (n = 214). Serial 4-dimensional CTs were performed at 30 days and 1 year and were analyzed independently by a core laboratory.
RESULTS: The incidence of HALT increased from 10% at 30 days to 24% at 1 year. Spontaneous resolution of 30-day HALT occurred in 54% of patients at 1 year, whereas new HALT appeared in 21% of patients at 1 year. HALT was more frequent in transcatheter versus surgical valves at 30 days (13% vs. 5%; p = 0.03), but not at 1 year (28% vs. 20%; p = 0.19). The presence of HALT did not significantly affect aortic valve mean gradients at 30 days or 1 year. Patients with HALT at both 30 days and 1 year, compared with those with no HALT at 30 days and 1 year, had significantly increased aortic valve gradients at 1 year (17.8 ± 2.2 mm Hg vs. 12.7. ± 0.3 mm Hg; p = 0.04).
CONCLUSIONS: Subclinical leaflet thrombosis was more frequent in transcatheter compared with surgical valves at 30 days, but not at 1 year. The impact of HALT on thromboembolic complications and structural valve degeneration needs further assessment.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypoattenuated leaflet thickening; leaflet thrombosis; reduced leaflet motion; subclinical leaflet thrombosis

Year:  2020        PMID: 32553252     DOI: 10.1016/j.jacc.2020.04.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Predictive Model for Thrombus Formation After Transcatheter Valve Replacement.

Authors:  Hoda Hatoum; Shelly Singh-Gryzbon; Fateme Esmailie; Philipp Ruile; Franz-Josef Neumann; Philipp Blanke; Vinod H Thourani; Ajit P Yoganathan; Lakshmi Prasad Dasi
Journal:  Cardiovasc Eng Technol       Date:  2021-12-02       Impact factor: 2.495

Review 2.  Transcatheter Aortic Valve Leaflet Thrombosis: Prevalence, Management, and Future Directions.

Authors:  Makoto Nakashima; Hasan Jilaihawi
Journal:  Curr Cardiol Rep       Date:  2021-11-11       Impact factor: 2.931

Review 3.  Early Leaflet Thickening, Durability and Bioprosthetic Valve Failure in TAVR.

Authors:  Brian C Case; Jaffar M Khan; Toby Rogers
Journal:  Interv Cardiol Clin       Date:  2021-10

4.  Mechanical aortic valve prostheses offer a survival benefit in 50-65 year olds: AUTHEARTVISIT study.

Authors:  Denise Traxler; Pavla Krotka; Maria Laggner; Michael Mildner; Alexandra Graf; Berthold Reichardt; Ralph Wendt; Johann Auer; Bernhard Moser; Julia Mascherbauer; Hendrik Jan Ankersmit
Journal:  Eur J Clin Invest       Date:  2021-12-30       Impact factor: 5.722

5.  Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.

Authors:  Hanbit Park; Do-Yoon Kang; Jung-Min Ahn; Kyung Won Kim; Anthony Y T Wong; Simon C C Lam; Wei-Hsian Yin; Jeng Wei; Yung-Tsai Lee; Hsien-Li Kao; Mao-Shin Lin; Tsung-Yu Ko; Won-Jang Kim; Se Hun Kang; Euihong Ko; Dae-Hee Kim; Hyun Jung Koo; Dong Hyun Yang; Joon-Won Kang; Seung Chai Jung; Jae-Hong Lee; Sung-Cheol Yun; Seung-Jung Park; Duk-Woo Park
Journal:  BMJ Open       Date:  2021-01-05       Impact factor: 2.692

6.  Commentary: Cause for concern or 1 in 33 million?

Authors:  Gaetano Paone
Journal:  JTCVS Tech       Date:  2020-10-22

7.  The year in cardiovascular medicine 2020: valvular heart disease.

Authors:  Javier Bermejo; Andrea Postigo; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2021-02-11       Impact factor: 29.983

8.  Subclinical Leaflets Thrombosis After Transcatheter Replacement of Bicuspid vs. Tricuspid Aortic Valve.

Authors:  Gangjie Zhu; Jiaqi Fan; Dao Zhou; Hanyi Dai; Qifeng Zhu; Yuxin He; Yuchao Guo; Lihan Wang; Xianbao Liu; Jian'an Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-22

Review 9.  Platelets: Implications in Aortic Valve Stenosis and Bioprosthetic Valve Dysfunction From Pathophysiology to Clinical Care.

Authors:  Stephanie L Sellers; Gaurav S Gulsin; Devyn Zaminski; Rong Bing; Azeem Latib; Janarthanan Sathananthan; Philippe Pibarot; Rihab Bouchareb
Journal:  JACC Basic Transl Sci       Date:  2021-11-17

10.  Highlights of the 15th annual scientific meeting of the Society of Cardiovascular Computed Tomography.

Authors:  Jonathan R Weir-McCall; Kelley Branch; Maros Ferencik; Ron Blankstein; Andrew D Choi; Brian B Ghoshhajra; Kavitha Chinnaiyan; Purvi Parwani; Edward Nicol; Koen Nieman
Journal:  J Cardiovasc Comput Tomogr       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.